Vertex Pharmaceuticals Inc

12 Jun 2026, 19:36 UTC

Vertex Pharmaceuticals shares are higher today, reflecting stable trading conditions. The stock is positioned above its 20-day moving average, indicating positive market sentiment.

11 Jun 2026, 23:56 UTC

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

10 Jun 2026, 20:03 UTC

Vertex Pharmaceuticals shares are lower as inflation data aligns with forecasts. The stock continues to trade below its 20-day moving average.

9 Jun 2026, 19:56 UTC

Vertex Pharmaceuticals shares are higher during Tuesday's session, having peaked earlier, though they have pulled back slightly. No specific news was identified for this movement.

8 Jun 2026, 19:36 UTC

Vertex Pharmaceuticals shares are lower despite positive data on ALYFTREK for cystic fibrosis. The decline follows broader market dynamics after a strong U.S. jobs report.

5 Jun 2026, 23:06 UTC

Vertex Pharmaceuticals shares are trading lower in after-market hours, with no specific news identified. Broader market conditions may be influencing the stock's movement.

4 Jun 2026, 20:02 UTC

RBC reiterated its Outperform rating on Vertex Pharmaceuticals with a $543 price target, contributing to shares advancing despite an earlier pullback.

3 Jun 2026, 23:06 UTC

Vertex Pharmaceuticals shares are trading higher in after-market hours. No specific news was identified to explain this movement amid broader market volatility.

2 Jun 2026, 20:03 UTC

Vertex Pharmaceuticals' FDA acceptance of povetacicept application fails to lift shares, which are trading lower and below their 20-day moving average.

1 Jun 2026, 19:41 UTC

Vertex Pharmaceuticals' Biologics License Application for povetacicept accepted by the FDA. Shares are lower today amid broader market sentiment despite this milestone.

29 May 2026, 22:06 UTC

Vertex Pharmaceuticals shares are higher in after-market hours, trading near the upper end of their one-month range and above their 20-day moving average.

28 May 2026, 20:02 UTC

Vertex Pharmaceuticals shares are higher today, continuing a steady upward trend since Wednesday. Broader market reactions to geopolitical tensions are influencing trading.

27 May 2026, 19:46 UTC

Truist Securities initiated coverage of Vertex Pharmaceuticals with a Buy rating and raised the price target to $542, contributing to today's price gain.

26 May 2026, 19:56 UTC

Vertex Pharmaceuticals shares are higher today, continuing recent upward momentum. No specific company news was identified to explain the price movement.

22 May 2026, 19:26 UTC

Vertex Pharmaceuticals shares are higher as Health Canada reviews suzetrigine, a new oral pain treatment. The stock shows modest gains since Thursday's close.

21 May 2026, 19:56 UTC

Vertex Pharmaceuticals shares rise as Health Canada reviews suzetrigine for acute pain treatment, marking a potential breakthrough in oral pain medication.

20 May 2026, 19:56 UTC

Vertex Pharmaceuticals is declining amid a presentation at the RBC Capital Markets Global Healthcare Conference, despite a generally positive analyst outlook for its pipeline.

19 May 2026, 23:26 UTC

Vertex Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains stable within its one-month trading range.

18 May 2026, 19:46 UTC

Vertex Pharmaceuticals shares are lower today, continuing a recent downward trend amid cautious investor sentiment and rising costs. No specific news was identified for the decline.

15 May 2026, 23:36 UTC

Vertex Pharmaceuticals shares are modestly higher in after-market hours. No specific news was identified to explain the movement.

14 May 2026, 19:16 UTC

Vertex Pharmaceuticals is declining today, having opened lower and reached a session low. Broader economic data may be influencing market concerns.

13 May 2026, 19:26 UTC

Vertex Pharmaceuticals is trading higher, maintaining gains since Tuesday amid market volatility and comments from Federal Reserve officials on inflation trends.

12 May 2026, 19:52 UTC

Vertex Pharmaceuticals reaches a five-week high amid strong market interest. Despite social media concerns over Journavx's effectiveness, the stock shows solid performance today.

11 May 2026, 19:16 UTC

Vertex Pharmaceuticals sees shares rise on strong cystic fibrosis growth. New therapies and expanded patient reach bolster positive revenue outlook, despite broader market fluctuations.

8 May 2026, 19:36 UTC

Vertex Pharmaceuticals trades higher today, despite no specific news. The stock remains 1.50% below its 20-day moving average, reflecting broader market weakness.

7 May 2026, 20:06 UTC

Vertex Pharmaceuticals faces stock decline despite CASGEVY's strong launch. The biotechnology sector downturn, including a drop in the iShares ETF, impacts its performance today.

6 May 2026, 19:56 UTC

Vertex Pharmaceuticals secures reimbursement for CASGEVY in Germany. This milestone enhances gene therapy access for severe sickle cell disease and beta thalassemia patients.

5 May 2026, 23:26 UTC

Vertex Pharmaceuticals Inc. sees slight after-hours decline. Trading below its 20-day moving average and near one-month low.

4 May 2026, 23:02 UTC

Vertex Pharmaceuticals faces pressure from biotech sector decline. Despite exceeding EPS estimates, revenue fell short, and halted VX-522 study dampens investor sentiment.